Safety and immunogenicity of neoadjuvant treatment using WT1-immunotherapeutic in combination with standard therapy in patients with WT1-positive Stage II/III breast cancer: a randomized Phase I study

PURPOSE: This Phase I, multicenter, randomized study (ClinicalTrials.gov NCT01220128) evaluated the safety and immunogenicity of recombinant Wilms’ tumor 1 (WT1) protein combined with the immunostimulant AS15 (WT1-immunotherapeutic) as neoadjuvant therapy administered concurrently with standard trea...

Descripción completa

Detalles Bibliográficos
Autores principales: Higgins, M., Curigliano, G., Dieras, V., Kuemmel, S., Kunz, G., Fasching, P. A., Campone, M., Bachelot, T., Krivorotko, P., Chan, S., Ferro, A., Schwartzberg, L., Gillet, M., De Sousa Alves, P. M., Wascotte, V., Lehmann, F. F., Goss, P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2017
Materias:
Clinical Trial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5332485/
https://www.ncbi.nlm.nih.gov/pubmed/28176175
http://dx.doi.org/10.1007/s10549-017-4130-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5332485/
https://www.ncbi.nlm.nih.gov/pubmed/28176175
http://dx.doi.org/10.1007/s10549-017-4130-y

Ejemplares similares